BNIP3L Antibody

PACO19310



Product Information	
Size:	Protein Background:
50ul	In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'- GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions. Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF- mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription.
Reactivity:	
Human, Mouse	
Source:	
Rabbit	
lsotype:	
lgG	
Applications:	
Elisa, IHC	
Recommended dilutions:	BNIP3L
ELISA:1:1000-1:2000, IHC:1:15-1:50	Uniprot
	O60238
	Synonyms:
	BCL2/adenovirus E1B 19kDa interacting protein 3-like
	Immunogen:
	Synthetic peptide of human BNIP3L.
	Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO19310(BNIP3L Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).

The image on the left is immunohistochemistry of paraffin-embedded Human gastic cancer tissue using PACO19310(BNIP3L Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).